Ampreloxetine (TD-9855)
Small molecule
Evidence outlook · program status
Discontinued (2026-03-03), after a negative readout
Theravance Biopharma decided to wind down the ampreloxetine program on 3 March 2026, after the Phase 3 CYPRESS study in neurogenic orthostatic hypotension due to MSA did not meet its primary endpoint. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
SEQUOIA NCT03750552 · Neurogenic Orthostatic Hypotension The study was randomized, quadruple-blind, placebo-controlled, and included 195 participants. Its primary clinical symptom endpoint was not met: the change in dizziness/lightheadedness score did not differ significantly from placebo (p=0.574), so the results provide well-controlled but unclear evidence of benefit. Registry: NCT03750552 | 3 | Change From Baseline in Orthostatic Hypotension Symptom Assessment (OHSA) Question #1 Score at Week 4 (Baseline and Week 4) 2021-07-21 | Change From Baseline in Orthostatic Hypotension Symptom Assessment (OHSA) Question #1 Score at Week 4 (Baseline and Week 4): Ampreloxetine -1.69 score on a scale (Standard Error 0.29) | Placebo -1.45 score on a scale (Standard Error 0.293) | Partial signal | link ↗ |
View 2 more trials
REDWOOD NCT03829657 · Parkinson's Disease In this Phase 3 randomized-withdrawal trial (Study 0170) in symptomatic neurogenic orthostatic hypotension, patients who responded to open-label ampreloxetine were randomized to continue it or switch to placebo. The single primary was the proportion with treatment failure at week 6 of the withdrawal period: 30% on ampreloxetine vs 42% on placebo, odds ratio 0.60 (95% CI 0.27 to 1.29, p=0.196). The difference was not significant, so the primary was missed. The study was terminated early. Source: CT.gov posted results. Registry: NCT03829657 | 3 | Proportion of Participants With Treatment Failure at Week 6 of RW Treatment Period (6-week randomized withdrawal period (Week 16 to Week 22)) 2021-11-10 | Treatment failure at week 6 of the randomized-withdrawal period: ampreloxetine 0.30 vs placebo 0.42 (model-based proportions, n=64 each); odds ratio 0.60 (95% CI 0.27 to 1.29), p=0.196 (CT.gov posted results). | not yet graded | link ↗ |
CYPRESS NCT05696717 · Neurogenic Orthostatic Hypotension The trial used real randomization, quadruple-blinding, and a placebo-controlled withdrawal design with about 100 participants, and it measured a validated symptom scale for orthostatic hypotension as its main outcome -- all solid design features. However, the company has reported that this primary comparison did not reach statistical significance, so despite the strong design, the trial did not demonstrate a clear benefit for ampreloxetine. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT05696717 | 3 | Change in OHSA composite score at Week 8 during the double-blind RW period (8-week randomized withdrawal period (Week 12 to Week 20)) 2026-01 | CYPRESS (NCT05696717), primary endpoint change in OHSA composite score at Week 8: result was not statistically significant. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other norepinephrine transporter drugs
viloxazine, Esreboxetine, Reboxetine. Compare all 4 norepinephrine transporter drugs
3 other tracked programmes target this mechanism, 3 of them ahead of this one.
This drug's own stage for Neurogenic Orthostatic Hypotension: Discontinued. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ampreloxetine (TD-9855): this drug | Discontinued | Small molecule | norepinephrine transporter | not yet graded | NCT05696717: CYPRESS (NCT05696717), primary endpoint change in OHSA composite score at Week 8: result was not statistically significant. missed NCT03750552: Change From Baseline in Orthostatic Hypotension Symptom Assessment (OHSA) Question #1 Score at Week 4 (Baseline and Week 4): Ampreloxetine -1.69 score on a scale (Standard Error 0.29) | Placebo -1.45 score on a scale (Standard Error 0.293) missed | |
| Droxidopa (Northera) | Approved | Small molecule | norepinephrine precursor | Partial signal | NCT01176240: 306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ) (Baseline, Week 8): Droxidopa -2.2 units on a scale (Standard Deviation 2.44) vs Placebo -2.1 units on a scale (Standard Deviation 2.49) | |
| Viloxazine (Qelbree) | Approved(overall) | Small molecule | norepinephrine transporter | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Esreboxetine | Phase 3(overall) | Small molecule | norepinephrine transporter | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Reboxetine | Phase 3(overall) | Small molecule | norepinephrine transporter | Partial signal(overall) | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent